首页> 外文期刊>Clinical cardiology. >Increased Restenosis Rates 12 Months After Coronary Implantation of the Sirolimus-Eluting YUKON-Choice Stent Compared to the Paclitaxel-Eluting TAXUS Stent
【24h】

Increased Restenosis Rates 12 Months After Coronary Implantation of the Sirolimus-Eluting YUKON-Choice Stent Compared to the Paclitaxel-Eluting TAXUS Stent

机译:与紫杉醇洗脱TAXUS支架相比,西罗莫司洗脱YUKON-Choice支架冠状动脉植入后12个月的再狭窄率增加

获取原文
           

摘要

Background Previously the polymer-free sirolimus-eluting YUKON-Choice stent (A) has demonstrated noninferiority compared to the polymer-based paclitaxel-eluting TAXUS stent (B). To test for long-term equivalency in unselected real-world coronary lesions of various complexities, we retrospectively compared both stents. Methods A total of 410 patients with symptomatic coronary artery disease (CAD) were treated with stent A (n = 205) or stent B (n = 205). Baseline clinical characteristics, lesion location, and length and the number of stents implanted per lesion were equally distributed. Clinical follow-up with assessment of major adverse cardiac events (MACE) and noncardiac deaths was obtained at 9 and 12 months. Results Nominal stent diameter and nominal length of the stented segment were without differences between the groups. The incidence of MACE after 12 months was significantly higher in group A (35.1%) compared to group B (16.6%, P = .001). This was mainly due to increased rates of target-lesion revascularizations in group A (13.7%) vs group B (4.4%, P = .005). No significant differences in target-vessel revascularizations and non-target-vessel revascularizations were observed. In group B, 1 stent thrombosis was documented (0.5%) vs none in group A ( P .05); in each group 1 myocardial infarction (MI), but no cardiac deaths occurred; 3 noncardiac deaths in group A (1.5%) vs 7 in group B (3.4%) were observed ( P = .3). Conclusions In contrast to our previous findings indicating no differences in MACE between patients treated with the polymer-free sirolimus-eluting YUKON-Choice stent and the polymer-based paclitaxel-eluting TAXUS stent at 6 months, we herewith show that 12 months after percutaneous coronary intervention (PCI) of real-world coronary lesions the YUKON stent appears to be inferior due to increased target-lesion revascularization (TLR) rates as a consequence of delayed restenosis. Copyright ? 2010 Wiley Periodicals, Inc.
机译:背景技术以前,与基于聚合物的紫杉醇洗脱的TAXUS支架(B)相比,无聚合物的西罗莫司洗脱的YUKON-Choice支架(A)表现出非劣效性。为了测试各种复杂性的未选择的现实世界中冠状动脉病变的长期等效性,我们回顾性比较了两种支架。方法采用支架A(205例)或支架B(205例)对410例有症状的冠心病患者进行治疗。基线临床特征,病变位置,长度和每个病变植入的支架数量均等分布。在9和12个月时进行了临床随访,评估了重大不良心脏事件(MACE)和非心脏死亡。结果两组之间的标称支架直径和支架段的标称长度无差异。与B组(16.6%,P = .001)相比,A组(35.1%)在12个月后发生MACE的发生率显着更高。这主要是由于A组(13.7%)比B组(4.4%,P = .005)的靶病变血运重建率增加。在目标血管血运重建和非目标血管血运重建方面未观察到显着差异。在B组中,有1个支架血栓形成(0.5%),而在A组中没有(P> .05)。每组1例心肌梗死(MI),但未发生心源性死亡。观察到A组3例非心脏死亡(1.5%),B组7例(3.4%)非心脏死亡(P = .3)。结论与我们先前的发现相反,在6个月时,使用无聚合物西罗莫司洗脱的YUKON-Choice支架和基于聚合物的紫杉醇洗脱的TAXUS支架治疗的患者在MACE方面无差异,我们在此显示经皮冠状动脉造影后12个月现实世界中冠状动脉病变的介入治疗(PCI)由于延迟再狭窄而导致的靶病变血运重建(TLR)率增加,YUKON支架似乎较差。版权? 2010 Wiley期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号